Information Provided By:
Fly News Breaks for November 21, 2019
Nov 21, 2019 | 13:57 EDT
Roth Capital analyst Zegbeh Jallah lowered her price target for GlycoMimetics to $9 from $12 after the company shifted the timeline regarding the readout of top-line clinical data for the ongoing Phase 3 study of uprolesela to sometime during 2021 from the end of 2020. Jallah, however, remains positive on the outlook of the program, and made no changes to the probability of success of uproleselan. Further, she remains bullish on GMI-1359, which she notes remains on track to readout during 2020. The analyst keeps a Buy rating on GlycoMimetics.
News For GLYC From the Last 2 Days
There are no results for your query GLYC